Resalis Therapeutics presented preclinical data on an antisense oligonucleotide (ASO) targeting miR‑22 that the company says induces durable, tissue‑level metabolic changes and healthier weight loss in animal models. Chief scientific officers described miR‑22 as a master regulator of fat production and metabolism; Resalis argues this mechanism could avoid appetite‑suppression drawbacks seen with GLP‑1 therapies. The company’s ASO approach is still preclinical but attracted attention at TIDES Europe as a potential alternative or complement to incretin‑based medicines.